Searched for
OLAPARIB
Cipla, Natco Pharma, Hetero Labs among Indian firms chosen to supply key generic drugs in ChinaIndian firms Hetero Labs Limited, Cipla Ltd, Annora Pharma Private Limited and Natco Pharma won the bids conducted by the Chinese health mi...- AstraZeneca Pharma India shares rise over 2% after CDSCO clears Imfinzi for new cancer useAstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line treatment for...
- AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drugAstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and...
- AstraZeneca Pharma gets CSDCO nod to import anti-cancer drug LynparzaAstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and 150mg doses. Th...
- DCGI orders withdrawal of cancer drug Olaparib for certain treatmentsThe Drug Controller General of India has requested the withdrawal of AstraZeneca's Olaparib tablets for certain cancer treatments due to po...
- Regulator asks state bodies to limit scope of key cancer drugIndia's drug regulatory authority has instructed state-level counterparts to mandate manufacturers of Olaparib tablets in 100 mg and 150 mg...
- Zydus launches anti-cancer generic drug olaparib in IndiaThe drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for a more tailored and effective tre...
- AstraZeneca bets on licencing deals, public-private partnerships for India growthBritish-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, re...
- Delhi HC bars Natco Pharma from selling cancer drug OlaparibThe Delhi High Court has prohibited Natco Pharma from producing and selling the cancer drug Olaparib, marketed as 'BRACANAT' or under any o...
- Natco Pharma submits application with USFDA for generic cancer drugThe company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV' certification with the US Food and Drug Ad...
- AstraZeneca India receives DCGI's nod to market drug treating breast cancerThe Drugs Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with ear...
- AstraZeneca working on vaccine to prevent and cure Covid: MD Gagandeep SinghAnglo-Swedish pharma company AstraZeneca has mobilised research efforts to advance the development of a novel coronavirus-neutralising long...
- Indian scientists identify new potential drug treatments for COVID-19Using a virtual screening of the DrugBank database, the research published in the journal Scientific Reports, identified a variety of as ye...
- Genetic tests gaining popularity for diagnosis & treatments in IndiaThe size of the industry, which is pegged at Rs 300-400 crore, has been growing at 30% annually.
- Jet Airways, TCS and Persistent Systems among top stocks to track todayHere's a look at the top stocks that may hog the limelight in Friday's session.
- New 3-in-1 blood test can transform the treatment of advanced prostate cancerThe test could help to extend or save lives, by targeting treatment more effectively.
- 'Combo therapy against ovarian, breast cancer can overcome drug resistance'Kolkata, Sep 26 (IANS) Bolstering the knowhow behind targeted cancer treatment, Indian scientists have offered a new rationale for combinat...
- Good cancer drug data helps AstraZeneca in Pfizer fightBritain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.
- AstraZeneca leaves door ajar to Pfizer, despite hurdlesAstraZeneca's boss said he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's ops int...
Load More
